Exploring US High Growth Tech Stocks

Over the last 7 days, the United States market has experienced a 3.0% drop, although it has risen by 4.6% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks requires careful consideration of their innovation potential and ability to capitalize on emerging trends within a dynamic market environment.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 232 stocks from our US High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

TG Therapeutics (NasdaqCM:TGTX)

Simply Wall St Growth Rating: ★★★★★★

Overview: TG Therapeutics, Inc. is a commercial stage biopharmaceutical company that specializes in developing and commercializing innovative treatments for B-cell mediated diseases globally, with a market cap of approximately $5.67 billion.

Operations: TG Therapeutics focuses on acquiring, developing, and commercializing novel treatments for B-cell mediated diseases. The company generates revenue primarily from its biotechnology segment, amounting to $329 million.

TG Therapeutics has demonstrated a robust growth trajectory, with revenue and earnings expanding at 26% and 37.6% annually, outpacing broader market averages significantly. This growth is underpinned by strategic R&D investments which have enabled recent advancements in their flagship product, BRIUMVI® for multiple sclerosis. Recent data presented at the American Academy of Neurology highlighted BRIUMVI's enhanced tolerability and consistent safety profile, potentially boosting its market adoption. Moreover, the company's proactive approach to capital management is evident from its recent share repurchase program totaling $7.89 million, underscoring confidence in its financial health and commitment to shareholder value. As TG Therapeutics continues to navigate the competitive biotech landscape, these factors collectively fortify its position within the high-growth tech sector in healthcare.

• Get an in-depth perspective on TG Therapeutics' performance by reading our health report here.

• Evaluate TG Therapeutics' historical performance by accessing our past performance report.

Legend Biotech (NasdaqGS:LEGN)

Simply Wall St Growth Rating: ★★★★★★

Overview: Legend Biotech Corporation is a biopharmaceutical company that focuses on discovering, developing, manufacturing, and commercializing novel cell therapies for oncology and other indications across the United States, China, and Europe with a market cap of approximately $6.20 billion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to $627.24 million. With a market cap of approximately $6.20 billion, it is involved in the development and commercialization of cell therapies targeting oncology and other medical conditions across key global markets.

Legend Biotech's remarkable turnaround is evidenced by a surge in quarterly revenue to $186.52 million from $79.46 million the previous year, alongside a shift from a significant net loss to a profit of $26.28 million. This financial rebound is part of a broader trend where annual revenue more than doubled to $627.24 million, reflecting an aggressive growth trajectory with an annualized increase of 26.7%. Despite current unprofitability on an annual basis, the company is on track for profitability within three years, supported by robust projected earnings growth of 55.2% per year and expected advancements in biotechnological innovations that outpace industry averages significantly.

• Click here and access our complete health analysis report to understand the dynamics of Legend Biotech.

• Assess Legend Biotech's past performance with our detailed historical performance reports.

Netflix (NasdaqGS:NFLX)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Netflix, Inc. is a company that offers entertainment services and has a market capitalization of approximately $417.61 billion.

Operations: The company generates revenue primarily through its streaming entertainment service, which brought in approximately $39 billion.

Netflix's strategic focus on expanding its marketing and creative partnerships in the Asia-Pacific region, exemplified by appointing Rebecca Nadilo as Director of Marketing Partnerships Creative, underscores its commitment to global growth. This move coincides with impressive financial performance; in Q1 2025, Netflix reported a revenue increase of 10.2% year-over-year, further bolstered by a notable net income surge to $1.87 billion from $938 million in the previous year. Additionally, the company's aggressive share repurchase program saw it buy back shares worth over $911 million in the last quarter of 2024 alone. These efforts reflect a robust strategy aimed at enhancing shareholder value and capitalizing on emerging market opportunities while maintaining a strong innovation trajectory through significant R&D investments.

• Take a closer look at Netflix's potential here in our health report.

• Gain insights into Netflix's historical performance by reviewing our past performance report.

Taking Advantage

• Navigate through the entire inventory of 232 US High Growth Tech and AI Stocks here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com